# Agha Shahzad Pervez Executive Chairman ## Career chronology - **Appointed 17 January 2022; service agreement commenced 3 May 2022: Viridis Mining & Minerals** — Executive Director / Executive Chairman. [Annual Report 2023]() (p. 11); [Annual Report 2024]() (pp. 2, 22) - **Earlier roles; exact dates unknown: Resonance Health** — Senior Financial Accountant, CFO and Company Secretary. [Annual Report 2023]() (p. 11); [Annual Report 2024]() (directors report, prior roles) - **Prior to 2023; exact dates unknown: Battery Age Minerals** — CFO. [Annual Report 2023]() (p. 11); [Balkan Mining and Minerals Board Changes]() (p. 1) - **Current directorship varies by source date; 2023 annual report and 2024 BMM notice confirm role, later issuer bio reports concurrent board positions: Equinox Resources** — Senior executive / director; concurrent NED per later disclosures. [Annual Report 2023]() (p. 11); [Balkan Mining and Minerals Board Changes]() (p. 1) ## Education and qualifications ### Accounting and information-technology qualifications [vmm_pervez_education] As reported 2023 and 2025 · issuer reported · medium materiality The 2023 Viridis annual report lists MCom and BSc IT qualifications; a 2025 issuer annual meeting document states BSc IT (Hons) and Master of Commerce (Professional Accounting). Degree institutions and completion dates are absent from the reviewed sources and were not independently checked. **Attribution:** Individual involvement documented. Company filings identify listed qualifications but do not provide independently verified award records. **Relevance:** Relevant to executive-chair financial oversight. [Annual Report 2023]() (p. 11, qualifications); [Board and Senior Leadership]() (current leadership biography) ## Contributions and company outcomes ### Resonance Health restructuring and market-capitalisation claim [vmm_pervez_rht] 2017 (issuer-reported) and his RHT tenure, dates not established · issuer reported · medium materiality Viridis’s 2023 annual report says Pervez was instrumental in Resonance Health’s 2017 corporate restructuring and contributed to significant market-capitalisation growth during his tenure. This is an issuer claim; the reviewed evidence does not specify his responsibilities, quantify shareholder return, or independently corroborate causation. **Attribution:** Individual involvement documented. The issuer attributes a contribution, but underlying restructuring filings and market data were not examined in this pass. **Relevance:** Potentially relevant capital restructuring experience, with attribution and outcome limits. [Annual Report 2023]() (p. 11, experience and expertise) ## Governance and interests ### Related-party consultancy fees disclosed by Viridis [vmm_pervez_relatedparty] FY2023–FY2024 · documented · medium materiality Viridis’s FY2024 report records a consultancy services agreement for Pervez commencing 3 May 2022 and fees paid to Horizon Corporate Advisory Pty Ltd, a company of Pervez, including an outstanding payable at 30 June 2024. This appears disclosed in the annual report; review here found no regulator finding or allegation arising from it. The disclosure is governance-relevant but is not itself evidence of misconduct. **Attribution:** Individual involvement documented. Audited annual report identifies related-party counterparty and amounts; no conclusion on arm’s-length terms or board approval process beyond disclosure was established. **Relevance:** Relevant to conflicts, board independence and related-party controls. [Annual Report 2024]() (pp. 53–54, related-party transactions; p. 22 service agreement) ## Suitability for the current role ### Role relevance and evidenced background [vmm_agha_pervez_fit] Background reviewed through 2026-10-09 · analyst inference · low materiality The issuer reports 13+ years with ASX-listed companies in director, CFO and company-secretary work and lists concurrent non-executive board roles. Current title in the selected roster: Executive Chairman. This supports role relevance at a high level; the public evidence reviewed does not establish personal causal responsibility for employer or project outcomes. **Attribution:** Responsibility not applicable. Role-fit judgment based on the selected roster and issuer-reported professional background; no causal claim is made. **Relevance:** Relevant to the current Executive Chairman responsibilities, subject to the evidence limitations recorded below. [Board and Senior Leadership]() (Executive biography or corporate-directory entry for the named person) ## Evidence gaps - Exact tenure dates and outcome evidence for Resonance Health, Battery Age Minerals and Equinox Resources roles remain incomplete; predecessor-company restructurings and financial outcomes were not independently researched. - Viridis FY2024 discloses related-party consultancy fees, but this review did not verify contract scope, competitive process, approval minutes or arm’s-length terms. - Credential records and complete current concurrent directorship list were not checked against professional or corporate registries. - Focused public-web adverse searches did not produce a substantiated personal enforcement result; no exhaustive regulator, court, sanctions, safety or environment screening was undertaken.